BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer	Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma	Active, not recruiting	Phase 3	2024-06-17		NCT06462001

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Australian and New Zealand Urogenital and Prostate Cancer Trials Group	10
Nottingham University Hospitals NHS Trust	53
University of Sydney	73

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Nottingham University Hospitals	Nottingham	United Kingdom	1

Clinical trials